



NOVA-BCL6-1

A first-in-human, multicenter study for a new drug (LY4584180) in adults who have already received treatment for blood cancers, to learn about its safety, tolerability, how the body processes it (pharmacokinetics), and how well it works (efficacy).

- Actively enrolling



What is BCL6?

- BCL6 stands for B-cell lymphoma 6
- It is a protein that helps B cells (a type of white blood cell that fights infections) grow and develop
- When BCL6 stays too active, it can cause B cells to grow uncontrollably and lead to cancer¹



What is a Molecular Glue and How Does it Work?

- Molecular glues are designed to redirect the cell's natural protein disposal system that helps the body break down or destroy disease-causing proteins
- Molecular glues work by gluing or sticking together the disease causing proteins, which sends a signal to the cell to destroy it. This reduces the availability of proteins involved in cancer cell growth²
- The drug in this study, LY4584180, is called a molecular glue and it is a type of protein degrader
- It works by binding to a protein called BCL6. This "glue" helps the cell break down and remove the protein. By removing BCL6, the drug may help stop cancer cells from growing³




Figure 1: LY4584180's Role as a Molecular Glue



What is the Main Goal of the Study?

The primary goal of the study is to learn about the safety, side effects, and effectiveness of the BCL6 molecular glue in people with certain blood cancers.

This study will also help researchers better understand:

- What side effects may occur, and how severe they are
- How the body processes and removes the BCL6 molecular glue
- If the molecular glue can help treat blood cancers



What is the Study Treatment Plan?

This is an open-label study, which means both the doctors and participants will know what treatment is being given.

- All participants will receive the study drug called the BCL6 molecular glue
- No placebo will be used in this study (a placebo is a substance that looks like a real drug but has no active medicine in it)
- The study drug will be taken by mouth (orally) in 28-day cycles



Who can Participate in the Study?

The study is for patients^{4,5}:

- Who are 18 years or older
- Who have a type of B-cell blood cancer and have already received at least two prior treatments
- Types of B-cell cancers that qualify:
 - Diffuse large B-cell lymphoma (DLBCL)
 - Follicular lymphoma (FL)
 - Mantle cell lymphoma (MCL)
 - Marginal zone lymphoma (MZL)

- Waldenström macroglobulinemia (WM)
- Lymphoplasmacytic lymphoma (LPL)
- Chronic lymphocytic leukemia (CLL)
- Small lymphocytic lymphoma (SLL)

- Who are able to attend clinic visits and follow the study plan, including hospital stays, lab tests, and monitoring
- Who have organs (such as liver, kidneys, and heart) that are working well



What are the Possible Benefits of Taking Part in the Study?

The benefits of taking part in the study are⁶:

- Getting actively involved in medical research
- Contributing to the advancement of medical research
- Participants do not need to have health insurance to take part
- Participants may be refunded for travel costs related to study participation

Participants who choose to take part, will receive the following at no cost:

- All study-related medicine
- All study-related care and check-ins
- Access to specialized doctors and researchers



What are the Possible Risks of Taking Part in the Study?

- Patients may feel weak, have low blood pressure, pain in their joints, cramps in their muscles. The medical team will check the patient's blood regularly and monitor closely for this potential risk^{5,a}
- Patient's cancer may or may not respond to the study drug. This means the treatment might work well for some patients, and may not for others^a

^aInvestigational therapies that are being studied have unknown risks that may occur.



Can a Participant Change Their Mind About Taking Part in the Study?

Taking part in the study is the participant's choice. If the participant decides to discontinue, they may leave the study at any time for any reason.

References:

1. Lioungue C, et al. *Int J Mol Sci.* 2024;25(20):10968.
2. Sasso JM, et al. *Biochemistry.* 2023;62(3):601–623.
3. Slabicki M, et al. *Nature.* 2020;588(7836):164–168.
4. <https://clinicaltrials.gov/study/NCT07226843> (Accessed December 31, 2025).
5. NCT07226843; NOVA-BCL6-1. <https://www.lillyoncologypipeline.com/molecule/bcl6-molecular-glue/clinical-trial/NCT07226843> (Accessed January 09, 2026).
6. LY4584180 Informed consent form. Eli Lilly and Company. 2025.

For more information, please visit the study website:



<https://clinicaltrials.gov/study/NCT07226843?term=2025-523601-16-00%20&rank=1>

Lilly Trials Support:
ClinicalTrials.gov@lilly.com
The use of the investigational medicine is experimental.
Not all risks are known. There is no guarantee that a participant's cancer will improve when taking part in this study.

There may be multiple sites in this clinical trial. If you have further questions or interest in this clinical trial, please contact -
Telephone: 1-877-285-4559 or 1-317-615-4559
Email: clinical_inquiry_hub@lilly.com